BlackRock
THRX

BlackRock’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

BlackRock’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,425,234
Closed -$5.77M – 5459
2023
Q4 		$5.77M Buy
1,425,234
+84,754
+6% +$259K ﹤0.01% 3635
2023
Q3 		$3.61M Buy
1,340,480
+6,612
+0.5% +$25.9K ﹤0.01% 3792
2023
Q2 		$12.4M Buy
1,333,868
+450,406
+51% +$4.44M ﹤0.01% 3307
2023
Q1 		$7.85M Buy
883,462
+18,405
+2% +$181K ﹤0.01% 3442
2022
Q4 		$4.31M Buy
865,057
+89,467
+12% +$524K ﹤0.01% 3792
2022
Q3 		$4.5M Buy
775,590
+88,231
+13% +$623K ﹤0.01% 3805
2022
Q2 		$3.8M Buy
687,359
+142,504
+26% +$1.18M ﹤0.01% 3948
2022
Q1 		$6.28M Buy
544,855
+11,592
+2% +$124K ﹤0.01% 3832
2021
Q4 		$6.76M Buy
+533,263
New +$8.05M ﹤0.01% 3871

BlackRock's THRX Position: Q1 2024 in Review

BlackRock sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 1,425,234 shares — an estimated $5.77M sold.

BlackRock first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $12.4M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • BlackRock reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 1,425,234 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $5.77M.
  • BlackRock first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • BlackRock's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $12.4M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.